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Background
The objective of the present analysis was to systematically examine the effect of intracoronary bone marrow cell (BMC) therapy on left ventricular function after ST-segment elevation myocardial infarction in various subgroups of patients by performing a collaborative meta-analysis of randomized controlled trials.
Methods
We identified all randomized controlled trials comparing intracoronary BMC infusion as treatment for ST-segment elevation myocardial infarction . We contacted the principal investigator for each participating trial to provide summary data with regard to different prespecified subgroups (age, diabetes mellitus, time from symptoms to percutaneous coronary intervention, infarct related artery, left ventricular (LV) end-diastolic volume index (EDVI), LV ejection fraction (EF), infarct size, presence of microvascular obstruction, timing of cell infusion, and injected cell number) and 3 different endpoints (change in LVEF, LVEDVI and LV end-systolic volume index (ESVI)).
Results
Data from 16 studies were combined including 1641 patients (984 cell therapy, 657 controls). The absolute improvement in LVEF was greater among BMC treated patients compared to controls: (2.55% increase, 95% Confidence Interval (CI) 1.83 to 3.26, p<0.001). Cell therapy significantly reduced LVEDVI and LVESVI (-3.17 mL/m², 95% CI -4.86 to -1.47, p<0.001; -2.60 mL/m², 95% CI 3.84 to -1.35, p<0.001, respectively). Treatment benefit in terms of LVEF improvement was more pronounced in younger patients (age <55, 3.38%, 95% CI 2.36 to 4.39) compared to older patients (age ≥55 years, 1.77%, 95% CI 0.80 to 2.74, p=0.03). This heterogeneity in treatment effect was also observed with respect to the reduction in LVEDVI and LVESVI. Moreover, patients with baseline LVEF<40% derived more benefit from intracoronary BMC therapy. LVEF improvement was 5.30%,
Introduction
Previous meta-analyses of randomized trials have shown that intracoronary bone marrow cell (BMC) infusion in ST-segment elevation myocardial infarction (STEMI) patients has moderate positive results on the recovery of left ventricular (LV) function.(1, 2) Based on more detailed analyses from the individual trials, certain subgroups seem to have more benefit.
In some studies, patients with long delay from onset symptoms to revascularization, larger myocardial infarction (anterior myocardial infarction) and reduced baseline LV ejection fraction (EF) were more likely to benefit from BMC therapy. (3) (4) (5) Regarding microvascular obstruction (MVO), the subgroup effect remains unclear since 2 studies reported different outcomes of BMC therapy in this patients group.(6, 7) Furthermore, aging and risk factors for coronary artery disease affect the functional activity of endogenous stem and progenitor cells in experimental models, thereby potentially limiting the therapeutic potential of these cells. (8) However, the individual trials have not been large enough to explore outcomes reliably within such subgroups. Identifying the characteristics of the patients who will ultimately benefit from cell therapy is essential to allow for efficient translation of this novel therapy to clinical practice. Therefore, the aim of this collaboration was to assess the effects of intracoronary BMC on LVEF, LV end-diastolic volume index (EDVI) and LV end-systolic volume index (ESVI) in various subgroups of STEMI patients based on pooled patient data.
Methods
Data sources and study selection
We performed a computerized literature search from 1980 to February 2013 of the Pubmed, Embase, Cochrane database, the Current Controlled Trials Register and KoreaMed, IndMed and LILACS by using search terms that included "bone marrow cells, "stem cell", "precursor cell", "progenitor cell", "myocardial ischemia", "myocardial infarction," "ischemic heart disease", "coronary heart disease", and "heart failure" (see Appendix1). Only English language publications were selected. Additionally, we manually searched the conference abstracts of the American Heart Association, American College of Cardiology, European Society of Cardiology and Transcatheter Cardiovascular Therapeutics to identify additional unpublished studies. Finally, the bibliographies of identified studies and relevant review articles were screened for potentially suitable studies.
We included a study if: 1) it was a randomized, controlled trial; 2) patients were included with a clinical diagnosis of STEMI, treated with percutaneous coronary intervention (PCI); 3) a single intracoronary infusion of autologous BMC (irrespective of the type and number of isolated cells) within one month after STEMI was compared to a control arm not receiving BMC (e.g. infusion of control media or standard treatment). Studies were excluded if: 1) there were less than 30 participants in the cell therapy arm; 2) follow-up was less than 3 months; 3) BMCs were cultured in vitro for longer than 1 day prior to intracoronary infusion, or 4) granulocyte colony-stimulating factor (G-CSF) or macrophage colony-stimulating factor (M-CSF) were administrated as co-intervention.
Study identification was done by two independent reviewers and disagreement was resolved by a third reviewer. A total of 26 randomized clinical trials were identified through literature search ( Figure 1 and Appendix 2). Out of these 26 studies, 16 had a cell therapy arm of 30 patients or more. Eventually, these 16 studies (5-7, 9-21) all agreed to participate in this collaborative overview and meta-analysis.
They provided the requested data, and vouched for the correctness of the data.
Endpoints, subgroups and data assembly
The following 3 endpoints were investigated in the analysis: change in LVEF (in %), LVESVI (in mL/m²), and LVEDVI (in mL/m²) from baseline to follow-up. The preferred follow-up duration was 6 months. If not available, outcome at 3 or 4 months was used.
The following subgroups were defined by the baseline characteristics : 1) age <55 years/ ≥55 years, 2) diabetes mellitus yes/no, 3) symptom to PCI time < 6 hours/ ≥6 hours, 4) infarct related artery left anterior descending artery / right coronary artery or left circumflex artery, 5) baseline LVEDVI <100 mL/m²/ ≥100 mL/m², 6) baseline LVEF <40% / ≥40%, 7) infarct size <20 g/≥20 g on Magnetic
Resonance Imaging (MRI), and 8) microvascular obstruction presence/absence on MRI. Furthermore, we requested data on 9) time from primary PCI to cell infusion <7 days/ ≥7 days and 10) total number of injected mononuclear BMC <10 8 / ≥10 8 . The subgroups cut-off points were chosen based on the results of the previous cell therapy studies. Lastly we compared 2 trial characteristics, namely type of imaging modality (MRI versus other) and study design (double blinded randomized controlled trials compared to open label studies).
The principal investigator of each identified trial provided summary data (number of patients and mean ± standard deviation (SD)) of the 3 different endpoints and 10 different prespecified subgroups.
For the current analysis, subgroups and baseline timing of the measurement of LV function were defined as reported in each of the individual trials. When several methods were used for outcome assessment, MRI data were preferentially included in the analysis, followed by single photon emission computed tomography, echocardiography and LV angiography.
Statistical analysis
An overall meta-analysis was performed of the change in the 3 outcomes (LVEF, LVESVI and LVEDVI), based on random-effects models using the method described by DerSimonian and Laird (22) . 
Results
The participating trials randomized 1641 patients to intracoronary cell therapy (n=984) or standard therapy (n=657). Characteristics of the studies included in this review are listed in Table 1 . Mean age across studies ranged from 50 -61 years. Six studies included only patients with an anterior myocardial infarction. All STEMI patients were treated with primary PCI, except in the FINCELL study where patients were treated with thrombolysis first and later with PCI and cell infusion (12 In this analysis, 1494 patients had complete baseline and follow-up LVEF measurement, 1427 patients complete LVEDVI measurements (5 patients were missing from one trial (5) and LVEDVI was not available in another trial n=62 (20)) and 1349 patients complete LVESVI measurements (5 patients missing from one trial (5) and LVESVI data was not available in 2 trials, n=62 and n=78 (12, 20) ).
Patient Characteristics
The absolute incremental improvement in LVEF was greater among BMC treated patients compared to controls: 2.55% increase ( 95% CI 1.83 to 3.26, p<0.001), Figure 2 . Assessment of publication bias using visual examination of the funnel plot of the primary publications indicated no significant publication bias (Appendix 4). There was heterogeneity across study outcomes (I2=70%)
Treatment benefit in terms of LVEF improvement was more pronounced in patients with baseline LVEF <40% (5.30%, 95% CI 4.27 to 6.33) compared to LVEF ≥40% (1.45%, 95% CI 0.60 to 2.31, p<0.001). Also, patients < 55 years of age had more benefit from BMC therapy (3.38%, 95% CI 2.36 to 4.39) compared to patients age ≥55 years (1.77%, 95% CI 0.80 to 2.74, p=0.03). No significant interaction was observed between other subgroups and LVEF.
The overall effect of change of LVEDVI was -3.17 mL/m² in favour of BMC treatment (95% CI -4.86
to -1.47, p=0.<0.001, Figure 3 ). This decrease was more pronounced in patient with age <55 years (-5.70 mL/m², 95% CI -9.18 to -2.21), compared to patients ≥55 years of age (-1.13 mL/m², 95% CI -4.58 to 2.32, p=0.001).
There was a significant decrease in change of LVESVI in the BMC group compared to the control group with a treatment effect of -2.60 mL/m 2 (95% CI -3.84 to -1.35, p<0.001, Figure 4) . Again, patients with age<55 years benefit most from BMC compared to age ≥55 years (-4.47 ml/m², 95% CI (Table 2) .
Discussion
In this collaborative meta-analysis, we found that autologous BMC infusion is associated with a moderate but statistically significant improvement of LV systolic function and remodeling in patients after ST-segment elevation myocardial infarction . This is reflected by a larger increase in LVEF and a greater decrease in LVESVI and LVEDVI in the treated population. In additional subgroup analyses, younger patients and patients with more depressed LVEF at baseline had the largest benefit from BMC infusion.
Previous meta-analyses have reported similar or somewhat larger benefit from BMC infusion then we observed. These meta-analyses reported, incremental LVEF changes of 2.7%(24) and 3.0% (2), to 4.0% (25) in the most recent meta-analysis. However, the last and most recent meta-analysis included all patients with ischemic heart disease, irrespective of study design (cohort study or randomized trials) (25) . Also, this meta-analysis conducted by Jeevanantham et al. did not include 3 large randomized controlled trials (BONAMI, HEBE, and REGENT trial) that were included in our analysis.
Moreover, we have included only trials with at least 30 patients in the treatment arm.
In our analysis, younger patients benefit more from cell therapy in terms of LV remodelling. Aging is a significant predictor of impairment of endothelium-dependent vasodilation and there is an increased risk of atherosclerotic disease and poor outcomes in older patients. The accumulation of risk factors in the older population is linked to a decrease in both the absolute number as well as the function of stem cells. (26) However, aging itself seems to have a very strong influence on stem cell function and is accompanied by a decline in the homeostatic and regenerative capacity of all tissues and organs.(27) Both experimental as well as clinical studies have shown lower absolute numbers as well as functionality of stem cells with increasing age (8, 28) . BMCs isolated from younger-aged rats showed increased efficacy in restoring LV function after myocardial infarction as compared to BMCs isolated from middle-aged rats. (28) In patients with chronic ischemic heart disease, a similar relation between age and stem cell function has been shown. (29, 30) In the conducted BMC therapy clinical trials, autologous BMCs are typically harvested from older patients who have recently suffered a myocardial infarction. In contrast, experimental studies in rodent models typically utilize donor BMCs isolated from young, healthy, inbred mice that are not the recipients. It has been postulated that this explains the much greater benefit of BMC therapy as observed in experimental studies. (31) This might also have important implications for the therapeutic application of cell therapy. Future research should therefore focus on elucidating the crucial differences between young and aged BMCs and to reverse or alter these characteristics before delivery in a clinical setting.
In addition to younger age, we observed that patients with a more severely depressed LVEF at baseline had larger benefit from cell therapy. In fact, the effect in patients with an EF over 40% was practically non-existent whereas in the group of patients with an EF<40% the increase was substantial showing an improvement of 5%. It is conceivable that such an improvement could alter the clinical outcome in this high-risk population. Again, this has implications for the design of future clinical trials. Especially at the present time, when most studies are designed as proof-of-principle studies instead of large clinicaloutcome studies, the selection of patients is of utmost importance and should contain subjects with the largest potential benefit of the intervention.
Although reduced LVEF is associated with the presence of microvascular obstruction and larger MRI infarct sizes, we did not find an association between the presence of microvascular obstruction or infarct size and the effects of BMC infusion. However, these MRI parameters were only present in less than 37% of the patients included in this analysis and therefore results should be interpreted with caution.
Diabetes mellitus is one of the key risk factors for coronary artery disease, and its prevalence is and it yet remains to be determined which is the most effective regimen.
Limitations
There are some limitations to our analysis that should be taken into account. As with any metaanalysis, limitations to the method include heterogeneity across trials. In particular, there are differences in terms of treatment characteristics including used cell dosage, cell isolation protocols, storage methods, and image modalities. Morover, in our analysis, we have excluded trials with a cell therapy arm <30 participants (number of excluded patients is 322 (16%)). We excluded the smaller 13 trials for several reasons. First, we believe that subgroup assessment in these trials are less valuable due to small numbers. Second, we feel that publication bias is a larger problem in these small trials.
Third, to our opinion, cell therapy involves a comprehensive protocol that involves a learning curve.
Conclusion
This is, to our knowledge, the first collaborative meta-analysis to assess the effects of intracoronary 
